Institut Curie, Orsay F-91405, France.
INSERM U1021, Centre Universitaire, Orsay F-91405, France.
Nat Commun. 2017 May 12;8:15262. doi: 10.1038/ncomms15262.
NRAS and its effector BRAF are frequently mutated in melanoma. Paradoxically, CRAF but not BRAF was shown to be critical for various RAS-driven cancers, raising the question of the role of RAF proteins in NRAS-induced melanoma. Here, using conditional ablation of Raf genes in NRAS-induced mouse melanoma models, we investigate their contribution in tumour progression, from the onset of benign tumours to malignant tumour maintenance. We show that BRAF expression is required for ERK activation and nevi development, demonstrating a critical role in the early stages of NRAS-driven melanoma. After melanoma formation, single Braf or Craf ablation is not sufficient to block tumour growth, showing redundant functions for RAF kinases. Finally, proliferation of resistant cells emerging in the absence of BRAF and CRAF remains dependent on ARAF-mediated ERK activation. These results reveal specific and compensatory functions for BRAF and CRAF and highlight an addiction to RAF signalling in NRAS-driven melanoma.
NRAS 和其效应物 BRAF 在黑色素瘤中经常发生突变。矛盾的是,尽管 CRAF 而不是 BRAF 被证明对各种 RAS 驱动的癌症至关重要,这就提出了 RAF 蛋白在 NRAS 诱导的黑色素瘤中的作用问题。在这里,我们使用条件性 Raf 基因敲除技术在 NRAS 诱导的小鼠黑色素瘤模型中研究了它们在肿瘤进展中的作用,从良性肿瘤的发生到恶性肿瘤的维持。我们表明,BRAF 表达对于 ERK 激活和痣的发育是必需的,这表明其在 NRAS 驱动的黑色素瘤的早期阶段发挥了关键作用。在黑色素瘤形成后,单一的 Braf 或 Craf 缺失不足以阻断肿瘤生长,表明 RAF 激酶具有冗余功能。最后,在 BRAF 和 CRAF 缺失的情况下,抗性细胞的增殖仍然依赖于 ARAF 介导的 ERK 激活。这些结果揭示了 BRAF 和 CRAF 的特定和补偿功能,并强调了 RAF 信号在 NRAS 驱动的黑色素瘤中的成瘾性。